STUDY QUESTION: Does the use of hCG as luteal phase support in natural cycle frozen embryo transfer (FET) increase the ongoing pregnancy rate?
Introduction
The live-birth rate is significantly higher with the use of luteal phase support in stimulated IVF cycles as shown in a Cochrane meta-analysis (van der Linden et al., 2011) and the efficacy of hCGs and progesterone is comparable (Fatemi et al., 2007; van der Linden et al., 2011) .
Stimulated IVF cycles are associated with a luteal phase defect (van der Linden et al., 2011) . The main cause of the luteal phase defect in stimulated IVF cycles is the supraphysiological levels of steroids secreted by multiple corpora lutea during the early luteal phase, which directly inhibit the LH release via negative feedback actions at the hypothalamic-pituitary level (Fauser and Devroey, 2003) . Other causes of the luteal phase defect include use of GnRH agonist or antagonist to prevent the premature LH surge and the removal of large quantities of granulosa cells during the oocyte retrieval procedure. The luteal phase defect commonly found in stimulated IVF cycles should not be encountered in natural cycle FET as only one follicle commonly develops and ovulates in natural cycles. However, this argument is subject to diagnostic difficulty and controversy.
Luteal phase support is commonly used in natural cycle frozen embryo transfer (FET) although there is little good evidence to support its role in natural cycles. A retrospective study using vaginal progesterone did not demonstrate any improvement in the ongoing pregnancy rate of natural cycle FET , and our retrospective analysis found no benefit of hCG in natural and clomid-induced cycle FET (Lee et al., 2013) . However, another retrospective study showed significantly higher ongoing pregnancy and live-birth rates with the use of progesterone in FET cycles (Kim et al., 2014) . Two randomized studies gave contradictory results; use of vaginal progesterone was associated with a significantly higher ongoing pregnancy rate (Bjuresten et al., 2011) while use of intramuscular progesterone caused no difference in the clinical pregnancy rate when compared with the control group although no placebo given (Eftekhar et al., 2013) .
This randomized double-blinded controlled trial aimed to compare the ongoing pregnancy rate in natural FET cycles with and without hCG as luteal phase support. The working hypothesis was that the use of hCG would increase the ongoing pregnancy rate of natural cycle FET.
Materials and Methods

Study population
Women attending the Centre of Assisted Reproduction and Embryology, The University of Hong Kong-Queen Mary Hospital for FET were screened by a dedicated research nurse. Inclusion criteria included: (i) regular menstrual cycles for natural cycle FET; (ii) normal uterine cavity shown on pelvic scanning during the stimulated IVF cycle; and (iii) endometrial thickness ≥8 mm in the FET cycle. Patients were excluded if they had: (i) irregular menstrual cycles requiring hormonal replacement cycles for FET; (ii) blastocyst transfer or cycles with preimplantation genetic diagnosis; (iii) oocyte donation; (iv) the presence of hydrosalpinx not corrected surgically prior to FET; (v) previous participation in this study before and (vi) not agreed to join the study. The University of Hong Kong/Hospital Authority Hong Kong West Cluster Institutional Review Board approved this study (Approval no: UW 12-263), which was registered in clinicaltrial. gov (identifier: NCT01931384).
Randomization
Eligible women were invited to join the study and those who agreed to join the study signed the consent form after counselling. They were randomized on the day of FET according to a computer-generated randomization list in a block of 10, by sealed, opaque envelopes into one of the two groups: (i) the treatment group receiving hCG 1500 IU on the day of FET and 6 days after FET and (ii) the control group receiving normal saline on these 2 days. The hCG and normal saline solutions were prepared by a research nurse who was not involved in the clinical care of women. Both women and clinicians were blinded to the allocation group.
Treatment regimens
The details of the procedures for the original ovarian stimulation, oocyte retrieval, handling of the gametes, cryopreservation of the embryos and FET were as previously described (Ng et al., 2000; Lee et al., 2011) . In the stimulated IVF cycle, women were allowed to have a maximum of two embryos replaced into the uterine cavity 2 days after the retrieval and surplus good quality embryos were frozen on the same day. Those who did not get pregnant in the stimulated IVF cycle and those who returned for a second pregnancy would undergo FET either in natural or hormonal replacement cycles, at least 2 months after the stimulated IVF cycle if they had at least one frozen embryo. In FET cycles, a maximum of two embryos can be replaced after thawing.
Women having regular ovulatory cycles underwent natural cycle FET whereas those with irregular cycles were offered hormonal replacement for FET. For natural cycle FET, they attended the clinic daily from 18 days before the next expected period for the determination of serum oestradiol (E2) and LH concentrations until the LH surge, which was defined by the LH level being above 20 IU/L and more than double the average of the LH levels over the past 3 days. If the results were in doubt, further blood tests including progesterone would be required. FET was performed on the third day after the LH surge, simulating the fresh IVF cycle with the oocyte retrieval the day after LH surge. Ultrasound scanning was performed to measure the endometrial thickness the day after the LH surge.
Embryos were graded as grade one to grade six according to the evenness of each blastomere and the percentage of fragmentation (Veeck, 1999) . Embryos of four cells and of grade one or two were regarded as top quality embryos in this study. No grading would be given if some of the blastomeres lysed upon thawing. Only embryos with more than 50% of blastomeres present after thawing were transferred. Up to two embryos were transferred per transfer. Serum E2, progesterone and hCG levels were checked 6 days after FET using commercially available kits (Architect chemiluminescent microparticle immunoassay, Abbott Laboratories, Abbott Ireland, Longford, Ireland). The sensitivity of the E2 assay is 10.0 pmol/mL and the intra-and interassay coefficients of variation (CV) are 1.8% and 1.7%, respectively. The sensitivity of the progesterone and hCG assay is 0.1 nmol/mL and 1.2 mIU/mL, respectively, and the intra-and inter-assay CVs are 1.9% and 2.0%, and 1.6% and 1.7%, respectively.
A urine pregnancy test was done around 2 weeks after FET. If it was positive, a pelvic ultrasound examination was performed 14 days later to confirm intrauterine pregnancy and foetal viability and to determine the number of gestational sacs present. Patients were referred out for antenatal care at 10-12 gestational weeks.
Outcome measures
The primary outcome measure was an ongoing pregnancy with a positive fetal pulsation on ultrasound beyond 10-12 gestational weeks. The secondary outcome measures were the miscarriage rate, the implantation rate, serum E2, progesterone and hCG levels 6 days after FET, positive pregnancy test, clinical pregnancy, live birth and multiple pregnancy rates. Miscarriage rate was defined as the number of miscarriage before 20 weeks divided by the number of women with a positive pregnancy test. Implantation rate was the number of gestational sacs per number of embryos transferred. Clinical pregnancy was defined as the presence of at least one gestational sac on ultrasound at 6 weeks. A baby born alive after 20 weeks gestation was classified as a live birth. Multiple pregnancy was diagnosed if there was more than one gestational sac detected on ultrasound at 6 weeks.
Statistical analysis
The Kolmogorov-Smirnov test was used to test the normal distribution of continuous variables. Results of continuous variables were given as mean ± SD if the data were normally distributed, and as median (25th-75th centiles) if they were not normally distributed. Statistical comparison was carried out as intention-to-treat by Student's T-test, Mann-Whitney U-test or Wilcoxon signed ranks test for continuous variables and Chi-square test or Fisher's Exact Test for categorical variables, where appropriate.
According to Bjuresten et al. (2011) , an improvement of live-birth rate by 50% was shown following the use of vaginal progesterone. Our ongoing pregnancy rate without luteal phase support was about 25% per transfer and we hypothesized that the use of hCG would increase the ongoing pregnancy rate to 37.5%, i.e. a 50% increase (Bjuresten 2011) . Thus the the sample size required was 215 in each group to give a power of 0.8 and Type I error of 0.05. Thus, allowing for some drop-outs, 450 subjects (i.e. 225 in each group) were recruited.
Statistical analysis was performed using the Statistical Program for Social Sciences (SPSS Inc., Version 24.0, Chicago, USA). The two-tailed value of P < 0.05 was considered statistically significant.
Results
Study population
A total of 1807 women attending for FET between August 2013 and October 2015 were screened (Fig. 1) . A total of 450 eligible women joined the present study: 225 women in the treatment group and 225 women in the control group. No embryos were transferred in 10 cycles (6 cycles in the treatment group and 4 cycles in the control group) as all embryos lysed upon thawing (Fig. 2 ).
There were no significant differences between the two groups in the age of the women during the index stimulated IVF cycle, cause/ duration of subfertility, body mass index, smoking history, percentage of primary subfertility, antral follicle count before stimulation and history of previous IVF treatment (Table I) . Regarding the index stimulated IVF cycle, the total dosage of gonadotrophins used was significantly higher in the control group and the total number of top quality embryos available for transfer or cryopreservation was significantly higher in the treatment group. Other parameters including the duration of stimulation, number of oocytes retrieved, serum progesterone level on the hCG day, endometrial thickness and live-birth rate were all comparable between the two groups.
Outcomes
The rates of ongoing pregnancy (60/225 (26.7%, 95% CI 21-32%) in the treatment group vs 70/225 (31.3%, 95% CI 25-37%) in the control group, odds ratio 1.242 (95% CI 0.825-1.869), P = 0.298), miscarriage, implantation, positive pregnancy test, clinical pregnancy, live birth and multiple pregnancy were similar between the two groups (Table II) . The analysis was repeated after exclusion of cancelled FET due to lysis of embryos and the results were unchanged (data not shown).
In the treatment group, there were significantly more cycles with top quality embryos transferred and significantly higher serum E2 level 6 days after FET (Table III) . The endometrial thickness, number of embryos transferred and the serum progesterone and hCG levels 6 days after FET were comparable between the two groups. There were no significant differences in the serum E2 and progesterone levels 6 days after FET between pregnant and non-pregnant women (oestradiol: 510 pmol/L (246-1598) vs 553 pmol/L (283-1312), respectively, P=0.313 (data presented as median (95% CI)) and progesterone: 57.1 nmol/L (23.3-137.1) vs 46.8 nmol/L (20.4-121.3), P = 0.108).
The univariate logistic regression revealed that the use of hCG for luteal phase support was not a significant factor for the ongoing pregnancy, while the age of women during the stimulated IVF cycle, endometrial thickness after the LH surge, number of embryos transferred and presence of top quality embryos after thawing were found to be significant factors. In the multivariate logistic regression, the number of embryos transferred remained the only significant factor predictive of the ongoing pregnancy rate of FET (Table IV) .
Discussion
This randomized double-blinded controlled trial found that the use of hCG as luteal phase support did not improve the ongoing pregnancy rate of natural cycle FET and the only significant factor predictive of the successful outcome was the number of embryos transferred. The results of this randomized trial confirmed the findings of our previous retrospective study in natural and clomid-induced FET cycles (Lee et al., 2013) , which showed no difference in the clinical pregnancy rate and miscarriage rate with or without luteal phase support.
The underlying reason for the use of luteal phase support, namely the luteal phase defect commonly found in stimulated IVF cycles, should not be encountered in natural cycle FET. The luteal phase defect was first described to be one of the possible factors for subfertility as early as 1949 (Jones, 1949) . Despite the decades after its first description, there is still no consensus on the proper diagnosis of this problem (Practice Committee of the American Society for Reproductive Medicine, 2015). Endometrial biopsy had been considered the 'gold standard' to diagnose luteal phase defect. However, randomized trials have revealed that endometrial biopsy is an imprecise tool for differentiating fertile women from women with luteal phase defect or subfertility, with up to 25% of cycles with delayed endometrial maturation and the histological dating not being related to fertility Murray et al., 2004) . Moreover, the inter-and intra-observer variability in the diagnosis of endometrial biopsy is high . The prevalence of a luteal phase defect in natural cycles in normo-ovulatory patients with primary or secondary subfertility was reported to be 8.1%, based on endometrial histology (Rosenberg et al., 1980) . Not only is the diagnosis difficult, but the treatment is another challenge for luteal phase defect. There is no evidence to suggest that progesterone is beneficial in natural cycles. To maintain the function of the corpus luteum and to progesterone production, hCG stimulation is used (Nosarka et al., 2005) .
In the treatment group in this study, serum E2 levels 6 days after FET were significantly higher than in the control group but the clinical significance of such a slight increase in serum E2 is doubtful. The serum progesterone level was not elevated after hCG injection in the treatment group. This may be related to the fact that the first hCG injection was given on the third day of the LH surge and the steriodogenic response to hCG depends on the age of the corpus luteum (Fritz et al., 1992 ). Moreover, serum progesterones level have been shown increase 1 day after hCG injection and remain elevated for 5-6 days (Beckers et al., 2000) . We checked serum hormonal levels once, at 6 days following the first hCG injection. Serum progesterone levels in the luteal phase are not correlated with pregnancy outcome of assisted reproduction (Araujo Jr et al., 1994) , and this was in the present study. Six patients had hCG levels higher than 10 IU/L 6 days after FET and five of them were from the treatment group. Two of these patients become pregnant, one with a term delivery and one with a miscarriage. One patient from the control group had a raised hCG level but did not become pregnant. Retrospectively she admitted that an intramuscular injection was given by a private doctor, although she was not given the details of the injection. We could only presume it was hCG as there was no other possible explanation for the raised hCG level.
It is difficult to compare our results with the previous randomized trials (Bjuresten et al., 2011) Progesterone level on the hCG day (nmol/L) 2.9 (1.9-5.7) 2.6 (1.2-3.8)
Number of oocytes retrieved 11 (7-15) 10 (7-14)
Total number of good quality embryos available
Endometrial thickness (mm) 12.1 (10.5-13.5) 12.2 (10.6-13.6)
Ongoing pregnancy rate in the index stimulated IVF cycle 68 (30.2%) 61 (27.1%)
Data presented as number (percentage) or median (25th-75th centiles). P-value non-significant unless specified. *P < 0.005. cycle FET used. We timed spontaneous ovulation by daily checking of serum LH levels, while others used the urine LH surge to time ovulation (Bjuresten et al., 2011) or hCG to trigger ovulation (Eftekhar et al., 2013) . Urine LH kits are more prone to errors (Ghazeeri et al., 1999; McGovern et al., 2004) .The pregnancy rate was significantly lower in the hCG-induced FET group as in a randomized trial . A recent retrospective analysis also revealed a significantly lower pregnancy rate with hCG-induced FET combined with LPS in form of a progesterone pessary than with natural cycle FET timed with natural LH surge without LPS (Montagut et al., 2016) . HCG was given as luteal phase support in the present study while vaginal (Bjuresten et al., 2011) or intramuscular (Eftekhar et al., 2013) progesterone was used in the other randomized trials. Another luteal phase support regimen, adding GnRH agonist, was tried in both retrospective (Haas et al., 2015) and prospective randomized crossover study (Seikkula et al., 2016) , showing improved pregnancy rates although the difference was not significant in the randomized trial. We did not anticipate that there would be any difference in the success of the natural cycle FET with hCG or progesterone, as the efficacy of hCG and progesterone is comparable in stimulated IVF cycles (Fatemi et al., 2007; van der Linden et al., 2011) . The strength of this study was the double-blinded design. In the two randomized trials (Bjuresten et al., 2011; Eftekhar et al., 2013) , the control group did not receive any treatment and it may raise the possibility of bias both from women and clinicians. Moreover in our study, the serum hCG level was checked in the mid-luteal phase so we could be sure that no violation of the protocol happened, except the one control subject mentioned above. There are limitations of our study. The primary outcome is the ongoing pregnancy rate beyond 10-12 weeks, as the hormonal control of early pregnancy shifts from the corpus luteum to the placenta by then (Speroff and Fritz, 2005) . However, we also traced and reported the live-birth rate. Only early cleaving stage embryos were transferred in the present study and the results may not be applicable to blastocyst transfers. We confined our study to cleavage stage embryo transfer because during the planning stage of this study, there were still only a few blastocyst transfers in our unit. We postulated that there would not be any difference in blastocyst transfer as well as the natural physiological environment would be the same during the implantation window. We chose to use hCG as luteal phase support in the present study instead of more commonly used vaginal progesterone because of the risk of ovarian hyperstimulation syndrome following hCG injections is minimal in natural cycles, and many women preferred to receive hCG injections instead of daily vaginal progesterone as luteal phase support. Moreover, we believed hCG injections can serve a similar purpose of increasing the progesterone levels during luteal phase as the progesterone pessary.
Treatment schedules for hCG are empirical and widely varied because the optimal dose, timing and frequency of administration has remained unexamined. We used 1500 IU on Day 4 and Day 10 after the spontaneous LH surge in the present study and would not continue luteal phase support when the women had a positive pregnant test. Other hCG regimens have been reported, including 1500 IU every 2 days (Beckers et al., 2000) or every 3-4 days (Tay and Lenton, 2005) , 2000 IU every 3 days (Artini et al., 1995; Mui Lam et al., 2008) , 2500 IU every 2 days (Martinez et al., 2000) , or 5000 IU every 3 days for two doses followed by 2500 IU 3 days later for one dose (Ludwig et al., 2001) . The hCG arising from pregnancy would appear on Day 12 to 14 after the ovulation trigger (Beckers et al., 2000) . Based on evidence from fresh cycles, there is no need to continue luteal phase support when the women were found to be pregnant as the endogenous hCG from early pregnancy would make up the lack of LH (Andersen et al., 2002; Fatemi et al., 2007) and this data can be extrapolated to use in FET. There is also some evidence to show the use of progesterone supplementation during first trimester through 7 weeks may delay miscarriage but not help improve the live-birth rate in fresh cycles (Proctor et al., 2006) .
In conclusion, hCG used for luteal phase support does not improve the ongoing pregnancy of natural cycle FET.
